Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Histone deacetylase as a therapeutic target
Autore:
Kramer, OH; Gottlicher, M; Heinzel, T;
Indirizzi:
Biomed Res Inst, D-60596 Frankfurt, Germany Biomed Res Inst Frankfurt Germany D-60596 st, D-60596 Frankfurt, Germany Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76344 Eggenstein, Germany Forschungszentrum Karlsruhe Eggenstein Germany D-76344 genstein, Germany
Titolo Testata:
TRENDS IN ENDOCRINOLOGY AND METABOLISM
fascicolo: 7, volume: 12, anno: 2001,
pagine: 294 - 300
SICI:
1043-2760(200109)12:7<294:HDAATT>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE PROMYELOCYTIC LEUKEMIA; SUBEROYLANILIDE HYDROXAMIC ACID; ACUTE MYELOID-LEUKEMIA; PLZF-RAR-ALPHA; TRICHOSTATIN-A; SODIUM-BUTYRATE; IN-VIVO; CELL-PROLIFERATION; ANTITUMOR-ACTIVITY; GROWTH-INHIBITION;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
80
Recensione:
Indirizzi per estratti:
Indirizzo: Heinzel, T Biomed Res Inst, Georg Speyer Haus,Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany Biomed Res Inst Georg Speyer Haus,Paul Ehrlich Str 42-44 Frankfurt Germany D-60596
Citazione:
O.H. Kramer et al., "Histone deacetylase as a therapeutic target", TRENDS ENDO, 12(7), 2001, pp. 294-300

Abstract

The maintenance of health depends on the coordinated and tightly regulatedexpression of genetic information. Certain forms of leukemia have become paradigms for the pathogenic role of aberrant repression of differentiation genes. In these acute leukemias, fusion proteins generated by chromosomal translocations no longer function as transcriptional activators, but insteadrepress target genes by recruiting histone deacetylases (HDACs). The potential benefit of HDAC inhibition has been established by the use of enzyme inhibitors in vitro and in a single reported case of experimental therapy. Because recently identified HDAC inhibitors appear to overcome many drawbacks of early inhibitory compounds in clinical use, the stage is set to test the therapeutic value of HDAC inhibition in leukemias and in other diseases,including solid tumors and aberrant hormonal signaling. This review summarizes the range of diseases expected to respond to HDAC inhibition.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 20:55:57